Your browser is no longer supported. Please, upgrade your browser.
Settings
GRTS Gritstone Oncology, Inc. daily Stock Chart
GRTS [NASD]
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.28 Insider Own2.30% Shs Outstand28.14M Perf Week11.63%
Market Cap353.72M Forward P/E- EPS next Y-2.46 Insider Trans- Shs Float26.93M Perf Month-3.75%
Income-64.80M PEG- EPS next Q-0.59 Inst Own51.20% Short Float7.81% Perf Quarter-46.96%
Sales0.10M P/S3684.58 EPS this Y-120.70% Inst Trans17.49% Short Ratio13.02 Perf Half Y-
Book/sh-3.62 P/B- EPS next Y20.10% ROA- Target Price24.67 Perf Year-
Cash/sh2.75 P/C4.57 EPS next 5Y- ROE- 52W Range10.89 - 32.90 Perf YTD-18.64%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.79% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low15.42% ATR1.19
Employees102 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)45.72 Volatility7.57% 8.86%
OptionableNo Debt/Eq- EPS Q/Q-24.20% Profit Margin- Rel Volume0.61 Prev Close11.99
ShortableYes LT Debt/Eq- EarningsFeb 27 BMO Payout- Avg Volume161.49K Price12.57
Recom- SMA20-1.91% SMA50-20.88% SMA200-27.80% Volume98,687 Change4.84%
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
Feb-20-19 04:00PM  Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference GlobeNewswire
Jan-06-19 08:00AM  Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-19 06:16PM  Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:11AM  2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma American City Business Journals
Dec-20-18 04:00PM  Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer GlobeNewswire -17.00%
Dec-19-18 04:17PM  TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors PR Newswire -9.32%
Dec-17-18 11:00AM  Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE GlobeNewswire -7.08%
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-10-18 07:00AM  Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead GlobeNewswire -11.37%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-14-18 08:00AM  Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals -5.55%
Sep-28-18 09:18AM  Gritstone Oncology expects to begin trading today, prices at $15 per share MarketWatch
07:24AM  [$$] Gritstone Oncology Prices Upsized IPO at Top of Range The Wall Street Journal
Sep-27-18 09:30PM  Gritstone Oncology Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.